PMI features the MMRF’s CoMMpass study (Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile).
Under the study, PCC, which includes Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals and several academic and non-profit entities, will provide scientific and financial support for the PMI.
The study will use the fund to follow 1,000 newly diagnosed multiple myeloma patients over five years to understand the molecular changes underpinning the progression of the disease.
MMRF and the Multiple Myeloma Research Consortium chief operating officer Walter Capone said the partnership with Bristol-Myers Squibb is a vital component of the PMI.
"We applaud Bristol-Myers Squibb and all of the members of the PCC for their vision, commitment, and support of our mission to accelerate the translation of research findings into therapeutic advancements for patients," Capone added.
"We look forward to working closely with the Bristol-Myers Squibb team to deliver personalized approaches to even more effectively treat this difficult disease."